Correlation Engine 2.0
Clear Search sequence regions


  • antibodies (3)
  • humans (7)
  • IGHV3 (1)
  • immunoglobulin (2)
  • sdAbs (12)
  • TNFR1 (1)
  • Sizes of these terms reflect their relevance to your search.

    Single-domain antibodies (sdAbs), the autonomous variable domains of camelid and shark heavy-chain antibodies, have many desirable properties as components of biologic drugs. However, their sequences may increase the risk of immunogenicity and antidrug antibody (ADA) development in humans, and thus, sdAbs are routinely humanized during development. Here, we review and summarize the available evidence regarding the factors governing immunogenicity of sdAbs and our current state of knowledge of strategies to mitigate immunogenicity risks by humanization. While several sdAb properties, including high homology of camelid VH Hs with human IGHV3 gene products, favor low immunogenicity in humans, epitopes absent in the human repertoire including the exposed VH :VL interface may be intrinsically immunogenic. While most clinical trials have demonstrated minimal sdAb immunogenicity, two notable exceptions (the tetrameric DR5-specific VH H TAS266 and the TNFR1-specific VH GSK1995057) illustrate that special caution must be taken in identifying preexisting ADAs against highly potent sdAbs. Nonhuman sequence alone does not adequately explain sdAb immunogenicity, as some camelid VH Hs are nonimmunogenic while some fully human VH s elicit ADAs. The presence of preexisting ADAs directed against the exposed C-termini of some sdAbs in a significant proportion of individuals awaits a molecular explanation. Whether sdAb humanization reduces or promotes immunogenicity remains unclear: reduction of nonhuman sequence content at the expense of introducing low-level aggregation in humanized variants may be counterproductive. Further work will establish thresholds for VH H and VNAR humanization to maximize human sequence content while avoiding loss of binding affinity and/or immunogenicity resulting from aggregation or decreased stability. © 2021 Her Majesty the Queen in Right of Canada The FEBS Journal © 2021 Federation of European Biochemical Societies. Reproduced with the permission of the Minister of National Research Council Canada.

    Citation

    Martin A Rossotti, Kasandra Bélanger, Kevin A Henry, Jamshid Tanha. Immunogenicity and humanization of single-domain antibodies. The FEBS journal. 2022 Jul;289(14):4304-4327

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33751827

    View Full Text